CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 12/23/25
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood CancerBenzinga • 12/22/25
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesGlobeNewsWire • 12/22/25
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?Zacks Investment Research • 12/10/25
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong BuySeeking Alpha • 12/04/25
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%The Motley Fool • 11/30/25
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A BuySeeking Alpha • 11/13/25
ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?The Motley Fool • 11/12/25
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss EstimatesZacks Investment Research • 11/11/25
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/25
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/10/25
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small studyReuters • 11/08/25
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid LoweringGlobeNewsWire • 11/08/25
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 11/07/25
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From NowThe Motley Fool • 11/04/25